메뉴 건너뛰기




Volumn 43, Issue 1, 2016, Pages 4-8

Psoriasis: Behind the scenes

Author keywords

interleukin 17; interleukin 23; interleukin 36 ; psoriasis; tumor necrosis factor

Indexed keywords

ADALIMUMAB; BRIAKINUMAB; BRODALUMAB; CYTOKINE; ETANERCEPT; GAMMA INTERFERON; GUSELKUMAB; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 36GAMMA; IXEKIZUMAB; SECUKINUMAB; TILDRAKIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB; BIOLOGICAL PRODUCT;

EID: 84962339118     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.13186     Document Type: Review
Times cited : (30)

References (88)
  • 2
    • 79953074627 scopus 로고    scopus 로고
    • Prevalence of dermatological disorders in Japan: A nationwide, cross-sectional, seasonal, multicenter, hospital-based study
    • Furue M, Yamazaki S, Jimbow K, et al,. Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional, seasonal, multicenter, hospital-based study. J Dermatol 2011; 38: 310-320.
    • (2011) J Dermatol , vol.38 , pp. 310-320
    • Furue, M.1    Yamazaki, S.2    Jimbow, K.3
  • 3
    • 84877774022 scopus 로고    scopus 로고
    • The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men
    • Hägg D, Eriksson M, Sundström A, Schmitt-Egenolf M,. The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. PLoS ONE 2013; 8: e63619.
    • (2013) PLoS ONE , vol.8 , pp. e63619
    • Hägg, D.1    Eriksson, M.2    Sundström, A.3    Schmitt-Egenolf, M.4
  • 4
    • 84883557886 scopus 로고    scopus 로고
    • Clinical study on psoriasis patients for past 30 years (1982-2012) in Seoul National University Hospital Psoriasis Clinic
    • Na SJ, Jo SJ, Youn JI,. Clinical study on psoriasis patients for past 30 years (1982-2012) in Seoul National University Hospital Psoriasis Clinic. J Dermatol 2013; 40: 731-735.
    • (2013) J Dermatol , vol.40 , pp. 731-735
    • Na, S.J.1    Jo, S.J.2    Youn, J.I.3
  • 5
    • 84920747894 scopus 로고    scopus 로고
    • Genome-wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms
    • Baurecht H, Hotze M, Brand S, et al,. Genome-wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms. Am J Hum Genet 2015; 96: 104-120.
    • (2015) Am J Hum Genet , vol.96 , pp. 104-120
    • Baurecht, H.1    Hotze, M.2    Brand, S.3
  • 6
    • 84891372710 scopus 로고    scopus 로고
    • A large-scale screen for coding variants predisposing to psoriasis
    • Tang H, Jin X, Li Y, et al,. A large-scale screen for coding variants predisposing to psoriasis. Nat Genet 2014; 46: 45-50.
    • (2014) Nat Genet , vol.46 , pp. 45-50
    • Tang, H.1    Jin, X.2    Li, Y.3
  • 7
    • 84872497387 scopus 로고    scopus 로고
    • Transcriptional regulatory network for psoriasis
    • Lu X, Du J, Liang J, et al,. Transcriptional regulatory network for psoriasis. J Dermatol 2013; 40: 48-53.
    • (2013) J Dermatol , vol.40 , pp. 48-53
    • Lu, X.1    Du, J.2    Liang, J.3
  • 8
    • 84962403206 scopus 로고    scopus 로고
    • CARD14 gene polymorphism c.C2458T (p.Arg820Trp) is associated with clinical features of psoriasis vulgaris in a Chinese cohort
    • Feng C, Wang T, Li SJ, et al,. CARD14 gene polymorphism c.C2458T (p.Arg820Trp) is associated with clinical features of psoriasis vulgaris in a Chinese cohort. J Dermatol 2015; doi: 10.1111/1346-8138.13039.
    • (2015) J Dermatol
    • Feng, C.1    Wang, T.2    Li, S.J.3
  • 9
    • 84905645216 scopus 로고    scopus 로고
    • HLA-C 12:02 is a susceptibility factor in late-onset type of psoriasis in Japanese
    • Mabuchi T, Ota T, Manabe Y, et al,. HLA-C 12:02 is a susceptibility factor in late-onset type of psoriasis in Japanese. J Dermatol 2014; 41: 697-704.
    • (2014) J Dermatol , vol.41 , pp. 697-704
    • Mabuchi, T.1    Ota, T.2    Manabe, Y.3
  • 10
    • 84883560723 scopus 로고    scopus 로고
    • Novel IL36RN mutation in a Japanese case of early onset generalized pustular psoriasis
    • Kanazawa N, Nakamura T, Mikita N, Furukawa F,. Novel IL36RN mutation in a Japanese case of early onset generalized pustular psoriasis. J Dermatol 2013; 40: 749-751.
    • (2013) J Dermatol , vol.40 , pp. 749-751
    • Kanazawa, N.1    Nakamura, T.2    Mikita, N.3    Furukawa, F.4
  • 11
    • 84937597306 scopus 로고    scopus 로고
    • Identification of Two Loci Associated with Generalized Pustular Psoriasis
    • Zhang Z, Ma Y, Zhang Z, et al,. Identification of Two Loci Associated with Generalized Pustular Psoriasis. J Invest Dermatol 2015; 135: 2132-2134.
    • (2015) J Invest Dermatol , vol.135 , pp. 2132-2134
    • Zhang, Z.1    Ma, Y.2    Zhang, Z.3
  • 12
    • 84926224828 scopus 로고    scopus 로고
    • IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis
    • Hussain S, Berki DM, Choon SE, et al,. IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J Allergy Clin Immunol 2015; 135: 1067-1070.
    • (2015) J Allergy Clin Immunol , vol.135 , pp. 1067-1070
    • Hussain, S.1    Berki, D.M.2    Choon, S.E.3
  • 13
    • 84884283813 scopus 로고    scopus 로고
    • Incidence of cardiovascular disease in individuals with psoriasis: A systematic review and meta-analysis
    • Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH,. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol 2013; 133: 2340-2346.
    • (2013) J Invest Dermatol , vol.133 , pp. 2340-2346
    • Samarasekera, E.J.1    Neilson, J.M.2    Warren, R.B.3    Parnham, J.4    Smith, C.H.5
  • 14
    • 84928419406 scopus 로고    scopus 로고
    • Psoriasis and cardiometabolic traits: Modest association but distinct genetic architectures
    • Koch M, Baurecht H, Ried JS, et al,. Psoriasis and cardiometabolic traits: modest association but distinct genetic architectures. J Invest Dermatol 2015; 135: 1283-1293.
    • (2015) J Invest Dermatol , vol.135 , pp. 1283-1293
    • Koch, M.1    Baurecht, H.2    Ried, J.S.3
  • 15
    • 84939432672 scopus 로고    scopus 로고
    • Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink
    • Parisi R, Rutter MK, Lunt M, et al,. Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink. J Invest Dermatol 2015; 135: 2189-2197.
    • (2015) J Invest Dermatol , vol.135 , pp. 2189-2197
    • Parisi, R.1    Rutter, M.K.2    Lunt, M.3
  • 16
    • 84886953964 scopus 로고    scopus 로고
    • Framingham Risk Score underestimates cardiovascular disease risk in severe psoriatic patients: Implications in cardiovascular risk factors management and primary prevention of cardiovascular disease
    • Torres T, Sales R, Vasconcelos C, et al,. Framingham Risk Score underestimates cardiovascular disease risk in severe psoriatic patients: implications in cardiovascular risk factors management and primary prevention of cardiovascular disease. J Dermatol 2013; 40: 923-926.
    • (2013) J Dermatol , vol.40 , pp. 923-926
    • Torres, T.1    Sales, R.2    Vasconcelos, C.3
  • 17
    • 39149111552 scopus 로고    scopus 로고
    • Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease
    • Wolf N, Quaranta M, Prescott NJ, et al,. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 2008; 45: 114-116.
    • (2008) J Med Genet , vol.45 , pp. 114-116
    • Wolf, N.1    Quaranta, M.2    Prescott, N.J.3
  • 18
    • 84877750779 scopus 로고    scopus 로고
    • Case of Vogt-Koyanagi-Harada disease with psoriasis vulgaris
    • Uchiyama M, Mitsuhashi Y, Okubo Y, Goto H, Tsuboi R,. Case of Vogt-Koyanagi-Harada disease with psoriasis vulgaris. J Dermatol 2013; 40: 355-356.
    • (2013) J Dermatol , vol.40 , pp. 355-356
    • Uchiyama, M.1    Mitsuhashi, Y.2    Okubo, Y.3    Goto, H.4    Tsuboi, R.5
  • 19
    • 84886951791 scopus 로고    scopus 로고
    • Psoriasis vulgaris associated with Vogt-Koyanagi-Harada syndrome
    • Takahashi H, Tsuji H, Iizuka H,. Psoriasis vulgaris associated with Vogt-Koyanagi-Harada syndrome. J Dermatol 2013; 40: 933-934.
    • (2013) J Dermatol , vol.40 , pp. 933-934
    • Takahashi, H.1    Tsuji, H.2    Iizuka, H.3
  • 20
    • 84878563091 scopus 로고    scopus 로고
    • Simultaneous diagnosis of Kaposi's sarcoma, psoriasis, vitiligo and monoclonal gammopathy of undetermined significance in an immunocompetent patient
    • Sorce M, Bongiorno MR,. Simultaneous diagnosis of Kaposi's sarcoma, psoriasis, vitiligo and monoclonal gammopathy of undetermined significance in an immunocompetent patient. J Dermatol 2013; 40: 479-480.
    • (2013) J Dermatol , vol.40 , pp. 479-480
    • Sorce, M.1    Bongiorno, M.R.2
  • 21
    • 84903814334 scopus 로고    scopus 로고
    • Immunoglobulin G4-related disease in a psoriasis vulgaris patient treated with ustekinumab
    • Kajihara I, Makino K, Ichihara A, et al,. Immunoglobulin G4-related disease in a psoriasis vulgaris patient treated with ustekinumab. J Dermatol 2014; 41: 670-671.
    • (2014) J Dermatol , vol.41 , pp. 670-671
    • Kajihara, I.1    Makino, K.2    Ichihara, A.3
  • 22
    • 84900033354 scopus 로고    scopus 로고
    • Three cases of psoriasis vulgaris associated with myasthenia gravis
    • Takahashi H, Tsuji H, Iizuk H,. Three cases of psoriasis vulgaris associated with myasthenia gravis. J Dermatol 2014; 41: 462-463.
    • (2014) J Dermatol , vol.41 , pp. 462-463
    • Takahashi, H.1    Tsuji, H.2    Iizuk, H.3
  • 23
    • 84914154389 scopus 로고    scopus 로고
    • Case of anti-laminin gamma-1 pemphigoid with antibody against C-terminal domain of BP180 in a patient with psoriasis vulgaris
    • Ansai S, Hashizume S, Kawana S, et al,. Case of anti-laminin gamma-1 pemphigoid with antibody against C-terminal domain of BP180 in a patient with psoriasis vulgaris. J Dermatol 2014; 41: 1031-1033.
    • (2014) J Dermatol , vol.41 , pp. 1031-1033
    • Ansai, S.1    Hashizume, S.2    Kawana, S.3
  • 24
    • 84926431257 scopus 로고    scopus 로고
    • Pemphigoid with antibodies to laminin γ1, BP180 and BP230, associated with psoriasis vulgaris: Successful disease control with cyclosporin
    • Imanishi A, Tateishi C, Imanishi H, et al,. Pemphigoid with antibodies to laminin γ1, BP180 and BP230, associated with psoriasis vulgaris: successful disease control with cyclosporin. J Dermatol 2015; 42: 394-397.
    • (2015) J Dermatol , vol.42 , pp. 394-397
    • Imanishi, A.1    Tateishi, C.2    Imanishi, H.3
  • 25
    • 84872501716 scopus 로고    scopus 로고
    • Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept
    • Nin M, Tokunaga D, Ishii N, et al,. Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept. J Dermatol 2013; 40: 55-56.
    • (2013) J Dermatol , vol.40 , pp. 55-56
    • Nin, M.1    Tokunaga, D.2    Ishii, N.3
  • 26
    • 84878604671 scopus 로고    scopus 로고
    • Profile of patients with psoriasis associated with hepatitis C virus infection
    • Imafuku S, Nakayama J,. Profile of patients with psoriasis associated with hepatitis C virus infection. J Dermatol 2013; 40: 428-433.
    • (2013) J Dermatol , vol.40 , pp. 428-433
    • Imafuku, S.1    Nakayama, J.2
  • 27
    • 84885187774 scopus 로고    scopus 로고
    • Possible association of hepatitis C virus infection with late-onset psoriasis: A hospital-based observational study
    • Imafuku S, Naito R, Nakayama J,. Possible association of hepatitis C virus infection with late-onset psoriasis: a hospital-based observational study. J Dermatol 2013; 40: 813-818.
    • (2013) J Dermatol , vol.40 , pp. 813-818
    • Imafuku, S.1    Naito, R.2    Nakayama, J.3
  • 28
    • 84865625777 scopus 로고    scopus 로고
    • Alcohol consumption and psoriatic risk: A meta-analysis of case-control studies
    • Zhu KJ, Zhu CY, Fan YM,. Alcohol consumption and psoriatic risk: a meta-analysis of case-control studies. J Dermatol 2012; 39: 770-773.
    • (2012) J Dermatol , vol.39 , pp. 770-773
    • Zhu, K.J.1    Zhu, C.Y.2    Fan, Y.M.3
  • 29
    • 84878600624 scopus 로고    scopus 로고
    • Alcohol consumption: Is it really a risk factor for psoriasis?
    • Brenaut E, Barnetche T, Misery L,. Alcohol consumption: is it really a risk factor for psoriasis? J Dermatol 2013; 40: 508.
    • (2013) J Dermatol , vol.40 , pp. 508
    • Brenaut, E.1    Barnetche, T.2    Misery, L.3
  • 30
    • 84878619334 scopus 로고    scopus 로고
    • Alcohol consumption: Is it really a risk factor for psoriasis?: Reply to Emilie Brenaut's letter
    • Zhu KJ, Zhu CY,. Alcohol consumption: is it really a risk factor for psoriasis?: Reply to Emilie Brenaut's letter. J Dermatol 2013; 40: 509.
    • (2013) J Dermatol , vol.40 , pp. 509
    • Zhu, K.J.1    Zhu, C.Y.2
  • 31
    • 84880308810 scopus 로고    scopus 로고
    • Alcohol consumption and psoriasis: A systematic literature review
    • Brenaut E, Horreau C, Pouplard C, et al,. Alcohol consumption and psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2013; 27 (Suppl 3): 30-35.
    • (2013) J Eur Acad Dermatol Venereol , vol.27 , pp. 30-35
    • Brenaut, E.1    Horreau, C.2    Pouplard, C.3
  • 32
    • 84857985148 scopus 로고    scopus 로고
    • The cellular and signaling networks linking the immune system and metabolism in disease
    • Osborn O, Olefsky JM,. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012; 18: 363-374.
    • (2012) Nat Med , vol.18 , pp. 363-374
    • Osborn, O.1    Olefsky, J.M.2
  • 33
    • 84955166784 scopus 로고    scopus 로고
    • Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cells
    • Shibata S, Tada Y, Hau CS, et al,. Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cells. Nat Commun 2015; 6: 7687.
    • (2015) Nat Commun , vol.6 , pp. 7687
    • Shibata, S.1    Tada, Y.2    Hau, C.S.3
  • 34
    • 79952434300 scopus 로고    scopus 로고
    • Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: Induction of elevated serum adiponectin levels following therapy
    • Shibata S, Tada Y, Hau C, et al,. Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy. Br J Dermatol 2011; 164: 667-670.
    • (2011) Br J Dermatol , vol.164 , pp. 667-670
    • Shibata, S.1    Tada, Y.2    Hau, C.3
  • 35
    • 84878585734 scopus 로고    scopus 로고
    • Serum level of adiponectin increases and those of leptin and resistin decrease following the treatment of psoriasis
    • Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H,. Serum level of adiponectin increases and those of leptin and resistin decrease following the treatment of psoriasis. J Dermatol 2013; 40: 475-476.
    • (2013) J Dermatol , vol.40 , pp. 475-476
    • Takahashi, H.1    Tsuji, H.2    Ishida-Yamamoto, A.3    Iizuka, H.4
  • 36
    • 84878560584 scopus 로고    scopus 로고
    • Adiponectin levels in patients with psoriasis: A meta-analysis
    • Zhu KJ, Shi G, Zhang C, et al,. Adiponectin levels in patients with psoriasis: a meta-analysis. J Dermatol 2013; 40: 438-442.
    • (2013) J Dermatol , vol.40 , pp. 438-442
    • Zhu, K.J.1    Shi, G.2    Zhang, C.3
  • 37
    • 84936891385 scopus 로고    scopus 로고
    • IL-12 and IL-23 cytokines: From discovery to targeted therapies for immune-mediated inflammatory diseases
    • Teng MW, Bowman EP, McElwee JJ, et al,. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med 2015; 21: 719-729.
    • (2015) Nat Med , vol.21 , pp. 719-729
    • Teng, M.W.1    Bowman, E.P.2    McElwee, J.J.3
  • 38
    • 84937642086 scopus 로고    scopus 로고
    • IL-23/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies
    • Blauvelt A, Lebwohl MG, Bissonnette R,. IL-23/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies. J Invest Dermatol 2015; 135: 1946-1953.
    • (2015) J Invest Dermatol , vol.135 , pp. 1946-1953
    • Blauvelt, A.1    Lebwohl, M.G.2    Bissonnette, R.3
  • 39
    • 34948862264 scopus 로고    scopus 로고
    • Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide
    • Lande R, Gregorio J, Facchinetti V, et al,. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007; 449: 564-569.
    • (2007) Nature , vol.449 , pp. 564-569
    • Lande, R.1    Gregorio, J.2    Facchinetti, V.3
  • 40
    • 22344438901 scopus 로고    scopus 로고
    • Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production
    • Nestle FO, Conrad C, Tun-Kyi A, et al,. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202: 135-143.
    • (2005) J Exp Med , vol.202 , pp. 135-143
    • Nestle, F.O.1    Conrad, C.2    Tun-Kyi, A.3
  • 41
    • 84856100861 scopus 로고    scopus 로고
    • Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands
    • Morizane S, Yamasaki K, Mühleisen B, et al,. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J Invest Dermatol 2012; 132: 135-143.
    • (2012) J Invest Dermatol , vol.132 , pp. 135-143
    • Morizane, S.1    Yamasaki, K.2    Mühleisen, B.3
  • 43
    • 0037449737 scopus 로고    scopus 로고
    • Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17
    • Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL,. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278: 1910-1914.
    • (2003) J Biol Chem , vol.278 , pp. 1910-1914
    • Aggarwal, S.1    Ghilardi, N.2    Xie, M.H.3    De Sauvage, F.J.4    Gurney, A.L.5
  • 44
    • 34249026701 scopus 로고    scopus 로고
    • Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17
    • LeibundGut-Landmann S, Gross O, Robinson MJ, et al,. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 2007; 8: 630-638.
    • (2007) Nat Immunol , vol.8 , pp. 630-638
    • LeibundGut-Landmann, S.1    Gross, O.2    Robinson, M.J.3
  • 45
    • 84866551186 scopus 로고    scopus 로고
    • Microbial-induced Th17: Superhero or supervillain?
    • McGeachy MJ, McSorley SJ,. Microbial-induced Th17: superhero or supervillain? J Immunol 2012; 189: 3285-3291.
    • (2012) J Immunol , vol.189 , pp. 3285-3291
    • McGeachy, M.J.1    McSorley, S.J.2
  • 46
    • 80052661515 scopus 로고    scopus 로고
    • Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis
    • Laggner U, Di Meglio P, Perera GK, et al,. Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis. J Immunol 2011; 187: 2783-2793.
    • (2011) J Immunol , vol.187 , pp. 2783-2793
    • Laggner, U.1    Di Meglio, P.2    Perera, G.K.3
  • 47
    • 84937945349 scopus 로고    scopus 로고
    • Inflammation induces dermal Vγ4+ γδT17 memory-like cells that travel to distant skin and accelerate secondary IL-17-driven responses
    • Ramírez-Valle F, Gray EE, Cyster JG,. Inflammation induces dermal Vγ4+ γδT17 memory-like cells that travel to distant skin and accelerate secondary IL-17-driven responses. Proc Natl Acad Sci USA 2015; 112: 8046-8051.
    • (2015) Proc Natl Acad Sci USA , vol.112 , pp. 8046-8051
    • Ramírez-Valle, F.1    Gray, E.E.2    Cyster, J.G.3
  • 48
    • 84930572248 scopus 로고    scopus 로고
    • Dermal γδ T cells - What have we learned?
    • O'Brien RL, Born WK,. Dermal γδ T cells-What have we learned? Cell Immunol 2015; 296: 62-69.
    • (2015) Cell Immunol , vol.296 , pp. 62-69
    • O'Brien, R.L.1    Born, W.K.2
  • 49
    • 84906215927 scopus 로고    scopus 로고
    • A new player on the psoriasis block: IL-17A- and IL-22-producing innate lymphoid cells
    • Ward NL, Umetsu DT,. A new player on the psoriasis block: IL-17A- and IL-22-producing innate lymphoid cells. J Invest Dermatol 2014; 134: 2305-2307.
    • (2014) J Invest Dermatol , vol.134 , pp. 2305-2307
    • Ward, N.L.1    Umetsu, D.T.2
  • 50
    • 84909959109 scopus 로고    scopus 로고
    • The IL-17A-producing CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cells
    • Teunissen MB, Yeremenko NG, Baeten DL, et al,. The IL-17A-producing CD8+ T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cells. J Invest Dermatol 2014; 134: 2898-2907.
    • (2014) J Invest Dermatol , vol.134 , pp. 2898-2907
    • Teunissen, M.B.1    Yeremenko, N.G.2    Baeten, D.L.3
  • 52
    • 84925209356 scopus 로고    scopus 로고
    • IL-17A production in human psoriatic blood and lesions by CD146+ T cells
    • Mehta NN, Dagur PK, Rose SM, et al,. IL-17A production in human psoriatic blood and lesions by CD146+ T cells. J Invest Dermatol 2015; 135: 311-314.
    • (2015) J Invest Dermatol , vol.135 , pp. 311-314
    • Mehta, N.N.1    Dagur, P.K.2    Rose, S.M.3
  • 53
    • 79951743212 scopus 로고    scopus 로고
    • Functional specialization of interleukin-17 family members
    • Iwakura Y, Ishigame H, Saijo S, Nakae S,. Functional specialization of interleukin-17 family members. Immunity 2011; 34: 149-162.
    • (2011) Immunity , vol.34 , pp. 149-162
    • Iwakura, Y.1    Ishigame, H.2    Saijo, S.3    Nakae, S.4
  • 54
    • 84906311286 scopus 로고    scopus 로고
    • IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms
    • Ha HL, Wang H, Pisitkun P, et al,. IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms. Proc Natl Acad Sci USA 2014; 111: E3422-E3431.
    • (2014) Proc Natl Acad Sci USA , vol.111 , pp. E3422-E3431
    • Ha, H.L.1    Wang, H.2    Pisitkun, P.3
  • 55
    • 84931566876 scopus 로고    scopus 로고
    • Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis
    • Reich K, Papp KA, Matheson RT, et al,. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. Exp Dermatol 2015; 24: 529-535.
    • (2015) Exp Dermatol , vol.24 , pp. 529-535
    • Reich, K.1    Papp, K.A.2    Matheson, R.T.3
  • 56
    • 84925381286 scopus 로고    scopus 로고
    • IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions
    • D'Erme AM, Wilsmann-Theis D, Wagenpfeil J, et al,. IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions. J Invest Dermatol 2015; 135: 1025-1032.
    • (2015) J Invest Dermatol , vol.135 , pp. 1025-1032
    • D'Erme, A.M.1    Wilsmann-Theis, D.2    Wagenpfeil, J.3
  • 57
    • 84925650548 scopus 로고    scopus 로고
    • IL-36γ sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease
    • Friedrich M, Tillack C, Wollenberg A, Schauber J, Brand S,. IL-36γ sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease. Inflamm Bowel Dis 2014; 20: 1891-1901.
    • (2014) Inflamm Bowel Dis , vol.20 , pp. 1891-1901
    • Friedrich, M.1    Tillack, C.2    Wollenberg, A.3    Schauber, J.4    Brand, S.5
  • 58
    • 84868613788 scopus 로고    scopus 로고
    • Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk
    • Tortola L, Rosenwald E, Abel B, et al,. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest 2012; 122: 3965-3976.
    • (2012) J Clin Invest , vol.122 , pp. 3965-3976
    • Tortola, L.1    Rosenwald, E.2    Abel, B.3
  • 60
    • 84922352134 scopus 로고    scopus 로고
    • The translational revolution and use of biologics in patients with inflammatory skin diseases
    • Noda S, Krueger JG, Guttman-Yassky E,. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol 2015; 135: 324-336.
    • (2015) J Allergy Clin Immunol , vol.135 , pp. 324-336
    • Noda, S.1    Krueger, J.G.2    Guttman-Yassky, E.3
  • 61
    • 84885180849 scopus 로고    scopus 로고
    • Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis
    • Shimauchi T, Hirakawa S, Suzuki T, et al,. Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis. J Dermatol 2013; 40: 805-812.
    • (2013) J Dermatol , vol.40 , pp. 805-812
    • Shimauchi, T.1    Hirakawa, S.2    Suzuki, T.3
  • 62
    • 84911936567 scopus 로고    scopus 로고
    • Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials with different time points
    • Puig L, López A, Vilarrasa E, García I,. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points. J Eur Acad Dermatol Venereol 2014; 28: 1633-1653.
    • (2014) J Eur Acad Dermatol Venereol , vol.28 , pp. 1633-1653
    • Puig, L.1    López, A.2    Vilarrasa, E.3    García, I.4
  • 63
    • 84904545875 scopus 로고    scopus 로고
    • Secukinumab in plaque psoriasis-results of two phase 3 trials
    • Langley RG, Elewski BE, Lebwohl M, et al,. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med 2014; 371: 326-338.
    • (2014) N Engl J Med , vol.371 , pp. 326-338
    • Langley, R.G.1    Elewski, B.E.2    Lebwohl, M.3
  • 64
    • 84859017988 scopus 로고    scopus 로고
    • Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis
    • Papp KA, Leonardi C, Menter A, et al,. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366: 1181-1189.
    • (2012) N Engl J Med , vol.366 , pp. 1181-1189
    • Papp, K.A.1    Leonardi, C.2    Menter, A.3
  • 65
    • 84938992082 scopus 로고    scopus 로고
    • Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials
    • S0140-6736(15)60125-8
    • Griffiths CE, Reich K, Lebwohl M, et al,. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; pii: S0140-6736(15)60125-8.
    • (2015) Lancet
    • Griffiths, C.E.1    Reich, K.2    Lebwohl, M.3
  • 66
    • 80051726086 scopus 로고    scopus 로고
    • Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
    • Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA,. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011; 165: 661-668.
    • (2011) Br J Dermatol , vol.165 , pp. 661-668
    • Strober, B.E.1    Crowley, J.J.2    Yamauchi, P.S.3    Olds, M.4    Williams, D.A.5
  • 67
    • 84945443119 scopus 로고    scopus 로고
    • Tildrakizumab (MK-3222), an Anti- IL-23p19 Monoclonal Antibody, Improves Psoriasis in a Phase 2b Randomized Placebo- Controlled Trial
    • Papp K, Thaçi D, Reich K, et al,. Tildrakizumab (MK-3222), an Anti- IL-23p19 Monoclonal Antibody, Improves Psoriasis in a Phase 2b Randomized Placebo- Controlled Trial. Br J Dermatol 2015; doi: 10.1111/bjd.13932.
    • (2015) Br J Dermatol
    • Papp, K.1    Thaçi, D.2    Reich, K.3
  • 68
    • 84936763292 scopus 로고    scopus 로고
    • A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
    • Gordon KB, Duffin KC, Bissonnette R, et al,. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N Engl J Med 2015; 373 (2): 136-144.
    • (2015) N Engl J Med , vol.373 , Issue.2 , pp. 136-144
    • Gordon, K.B.1    Duffin, K.C.2    Bissonnette, R.3
  • 69
    • 84915805860 scopus 로고    scopus 로고
    • Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study
    • Ohtsuki M, Morita A, Abe M, et al,. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol 2014; 41: 1039-1046.
    • (2014) J Dermatol , vol.41 , pp. 1039-1046
    • Ohtsuki, M.1    Morita, A.2    Abe, M.3
  • 70
    • 84876003723 scopus 로고    scopus 로고
    • Long-term efficacy of psoriasis vulgaris treatments: Analysis of treatment with topical corticosteroid and/or vitamin D3 analog, oral cyclosporin, etretinate and phototherapy over a 35-year period, 1975-2010
    • Akasaka E, Mabuchi T, Manabe Y, et al,. Long-term efficacy of psoriasis vulgaris treatments: analysis of treatment with topical corticosteroid and/or vitamin D3 analog, oral cyclosporin, etretinate and phototherapy over a 35-year period, 1975-2010. J Dermatol 2013; 40: 238-243.
    • (2013) J Dermatol , vol.40 , pp. 238-243
    • Akasaka, E.1    Mabuchi, T.2    Manabe, Y.3
  • 71
    • 84903814736 scopus 로고    scopus 로고
    • Remission period in psoriasis after multiple cycles of narrowband ultraviolet B phototherapy
    • Ryu HH, Choe YS, Jo S, Youn JI, Jo SJ,. Remission period in psoriasis after multiple cycles of narrowband ultraviolet B phototherapy. J Dermatol 2014; 41: 622-627.
    • (2014) J Dermatol , vol.41 , pp. 622-627
    • Ryu, H.H.1    Choe, Y.S.2    Jo, S.3    Youn, J.I.4    Jo, S.J.5
  • 72
    • 84899998616 scopus 로고    scopus 로고
    • Efficacious treatment of psoriasis with low-dose and intermittent cyclosporin microemulsion therapy
    • Ito T, Furukawa F, Iwatsuki K, et al,. Efficacious treatment of psoriasis with low-dose and intermittent cyclosporin microemulsion therapy. J Dermatol 2014; 41: 377-381.
    • (2014) J Dermatol , vol.41 , pp. 377-381
    • Ito, T.1    Furukawa, F.2    Iwatsuki, K.3
  • 73
    • 84878584345 scopus 로고    scopus 로고
    • Comparison of clinical effects of psoriasis treatment regimens among calcipotriol alone, narrowband ultraviolet B phototherapy alone, combination of calcipotriol and narrowband ultraviolet B phototherapy once a week, and combination of calcipotriol and narrowband ultraviolet B phototherapy more than twice a week
    • Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H,. Comparison of clinical effects of psoriasis treatment regimens among calcipotriol alone, narrowband ultraviolet B phototherapy alone, combination of calcipotriol and narrowband ultraviolet B phototherapy once a week, and combination of calcipotriol and narrowband ultraviolet B phototherapy more than twice a week. J Dermatol 2013; 40: 424-427.
    • (2013) J Dermatol , vol.40 , pp. 424-427
    • Takahashi, H.1    Tsuji, H.2    Ishida-Yamamoto, A.3    Iizuka, H.4
  • 74
    • 84913553366 scopus 로고    scopus 로고
    • Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis
    • Hayashi M, Umezawa Y, Fukuchi O, et al,. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. J Dermatol 2014; 41: 974-980.
    • (2014) J Dermatol , vol.41 , pp. 974-980
    • Hayashi, M.1    Umezawa, Y.2    Fukuchi, O.3
  • 75
    • 84934444687 scopus 로고    scopus 로고
    • Ustekinumab treatment in patients with psoriasis undergoing hemodialysis
    • Umezawa Y, Hayashi M, Kikuchi S, et al,. Ustekinumab treatment in patients with psoriasis undergoing hemodialysis. J Dermatol 2015; 42: 731-744.
    • (2015) J Dermatol , vol.42 , pp. 731-744
    • Umezawa, Y.1    Hayashi, M.2    Kikuchi, S.3
  • 76
    • 84934444267 scopus 로고    scopus 로고
    • Successful adalimumab treatment of a psoriasis vulgaris patient with hemodialysis for renal failure: A case report and a review of the previous reports on biologic treatments for psoriasis patients with hemodialysis for renal failure
    • Kusakari Y, Yamasaki K, Takahashi T, et al,. Successful adalimumab treatment of a psoriasis vulgaris patient with hemodialysis for renal failure: A case report and a review of the previous reports on biologic treatments for psoriasis patients with hemodialysis for renal failure. J Dermatol 2015; 42: 727-730.
    • (2015) J Dermatol , vol.42 , pp. 727-730
    • Kusakari, Y.1    Yamasaki, K.2    Takahashi, T.3
  • 77
    • 84947024119 scopus 로고    scopus 로고
    • Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
    • Warren RB, Smith CH, Yiu ZZ, et al,. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol 2015; doi: 10.1038/jid.2015.208.
    • (2015) J Invest Dermatol
    • Warren, R.B.1    Smith, C.H.2    Yiu, Z.Z.3
  • 78
    • 84890441414 scopus 로고    scopus 로고
    • Drug survival rates in patients with psoriasis after treatment with biologics
    • Umezawa Y, Nobeyama Y, Hayashi M, et al,. Drug survival rates in patients with psoriasis after treatment with biologics. J Dermatol 2013; 40: 1008-1013.
    • (2013) J Dermatol , vol.40 , pp. 1008-1013
    • Umezawa, Y.1    Nobeyama, Y.2    Hayashi, M.3
  • 79
    • 84925230736 scopus 로고    scopus 로고
    • Immunogenicity of biotherapy used in psoriasis: The science behind the scenes
    • Jullien D, Prinz JC, Nestle FO,. Immunogenicity of biotherapy used in psoriasis: the science behind the scenes. J Invest Dermatol 2015; 135: 31-38.
    • (2015) J Invest Dermatol , vol.135 , pp. 31-38
    • Jullien, D.1    Prinz, J.C.2    Nestle, F.O.3
  • 80
    • 84877781173 scopus 로고    scopus 로고
    • Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: Report of two cases
    • Matsumoto Y, Maeda T, Tsuboi R, Okubo Y,. Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: report of two cases. J Dermatol 2013; 40: 389-392.
    • (2013) J Dermatol , vol.40 , pp. 389-392
    • Matsumoto, Y.1    Maeda, T.2    Tsuboi, R.3    Okubo, Y.4
  • 81
    • 84920511919 scopus 로고    scopus 로고
    • Efficacy of adalimumab and methotrexate combination therapy on generalized pustular psoriasis patients unresponsive to infliximab monotherapy due to anti-infliximab antibody development
    • Kawakami H, Maeda T, Abe N, et al,. Efficacy of adalimumab and methotrexate combination therapy on generalized pustular psoriasis patients unresponsive to infliximab monotherapy due to anti-infliximab antibody development. J Dermatol 2015; 42: 94-95.
    • (2015) J Dermatol , vol.42 , pp. 94-95
    • Kawakami, H.1    Maeda, T.2    Abe, N.3
  • 82
    • 84872489883 scopus 로고    scopus 로고
    • Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis
    • Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H,. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J Dermatol 2013; 40: 39-42.
    • (2013) J Dermatol , vol.40 , pp. 39-42
    • Takahashi, H.1    Tsuji, H.2    Ishida-Yamamoto, A.3    Iizuka, H.4
  • 83
    • 84883516165 scopus 로고    scopus 로고
    • Japanese guidance for use of biologics for psoriasis (the 2013 version)
    • Ohtsuki M, Terui T, Ozawa A, et al,. Japanese guidance for use of biologics for psoriasis (the 2013 version). J Dermatol 2013; 40: 683-695.
    • (2013) J Dermatol , vol.40 , pp. 683-695
    • Ohtsuki, M.1    Terui, T.2    Ozawa, A.3
  • 84
    • 84878585020 scopus 로고    scopus 로고
    • Development of miliary tuberculosis related to anti-tumor necrosis factor-alpha inhibitor therapy for pustular psoriasis
    • Koga M, Terawaki S, Tatsukawa R, et al,. Development of miliary tuberculosis related to anti-tumor necrosis factor-alpha inhibitor therapy for pustular psoriasis. J Dermatol 2013; 40: 476-477.
    • (2013) J Dermatol , vol.40 , pp. 476-477
    • Koga, M.1    Terawaki, S.2    Tatsukawa, R.3
  • 85
    • 84895068985 scopus 로고    scopus 로고
    • Risk of herpes zoster in psoriatic patients undergoing biologic treatment
    • Umezawa Y, Fukuchi O, Ito T, et al,. Risk of herpes zoster in psoriatic patients undergoing biologic treatment. J Dermatol 2014; 41: 168-170.
    • (2014) J Dermatol , vol.41 , pp. 168-170
    • Umezawa, Y.1    Fukuchi, O.2    Ito, T.3
  • 86
    • 84886954078 scopus 로고    scopus 로고
    • Generalized pustular psoriasis triggered by infliximab in two patients with Crohn's disease
    • Kato Y, Yamamoto T,. Generalized pustular psoriasis triggered by infliximab in two patients with Crohn's disease. J Dermatol 2013; 40: 932-933.
    • (2013) J Dermatol , vol.40 , pp. 932-933
    • Kato, Y.1    Yamamoto, T.2
  • 87
    • 84940732204 scopus 로고    scopus 로고
    • Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study
    • Pugliese D, Guidi L, Ferraro PM, et al,. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther 2015; 42: 880-888.
    • (2015) Aliment Pharmacol Ther , vol.42 , pp. 880-888
    • Pugliese, D.1    Guidi, L.2    Ferraro, P.M.3
  • 88
    • 84915798381 scopus 로고    scopus 로고
    • Elevation of serum KL-6 levels during treatment with tumor necrosis factor-α inhibitor in patients with psoriasis
    • Mabuchi T, Yamaoka H, Kawai M, Ota T, Ozawa A,. Elevation of serum KL-6 levels during treatment with tumor necrosis factor-α inhibitor in patients with psoriasis. J Dermatol 2014; 41: 1136-1137.
    • (2014) J Dermatol , vol.41 , pp. 1136-1137
    • Mabuchi, T.1    Yamaoka, H.2    Kawai, M.3    Ota, T.4    Ozawa, A.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.